Pre-existing HLA antibodies negatively impact long-term graft survival and might be a major risk factor for the formation of new HLA antibodies. Whether conversion of transplant recipients from calcineurin inhibitors to mammalian target of rapamycin inhibitors increases the risk of allosensitization remains to be determined.
